Earnings Briefs: Mylan, AbbVie, Vertex, Novo Nordisk, Gilead, Acorda
Executive Summary
Mylan sticks with Abbott deal, confident that it will be a successful tax inversion, while AbbVie rules out similar deals after walking away from Shire upon deciding recent tax policy changes rule out its own inversion play. Other updates from the third-quarter earnings calls, in brief.